May 13, 2020 05:02 PM EDTUpdated 05:24 PM
R&D

Macro­Gen­ics chief Scott Koenig de­tails the up­beat can­cer drug da­ta from 2 pro­grams that drove a big spike in their share price

John Carroll

Editor & Founder

Macro­Gen­ics $MGNX dropped their AS­CO ab­stracts on 2 key drug pro­grams on Wednes­day evening, high­light­ing some ad­di­tion­al de­tails on da­ta that spurred their share …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times